Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.

Sara Elena Rebuzzi,Sebastiano Buti,Luca Galli,Giuseppe Procopio,Ugo De Giorgi,Cinzia Baldessari,Francesco Massari,Daniele Santini,Alessia Cavo,Giuseppe Luigi Banna,Mariella Sorarů,Alessio Cortellini,Marco Messina,Valentino Martelli,Alessandra Damassi,Andrea Sbrana,Giulia Apollonio,Chiara Casadei,Alessio Signori,Giuseppe Fornarini

Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: Preliminary results of the Meet-URO 15 (I-BIO-REC) study.

2020

752Background: Biomarkers to select mRCC patients most likely to benefit to immune-checkpoint inhibitors are still needed. The ongoing retrospective multicentre Meet-URO 15 (I-BIO-REC) study evalua...

Keywords:

Oncology
Pathology
Nivolumab
Renal cell carcinoma
Neutrophil to lymphocyte ratio
Medicine
Internal medicine
Biomarker (medicine)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations